You are here: Industry Insights > avelumab

News List

Merck and Pfizer provide update on avelumab in platinum-resistant/refractory ovarian cancer worldpharmanews
November 21, 2018
Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxorubicin (PLD)
Immutep collaborates with Merck, Pfizer for Efti biospectrum
September 26, 2018
The clinical trial will evaluate the clinical benefits of releasing the brakes and pushing the accelerator of the body’s immune system at two different positions in the cancer immunity cycle.
NICE Positive Recommendation Supports Use of Bavencio (Avelumab) for Treatment of Adults in England, firstwordpharma
March 02, 2018
NICE has issued a Final Appraisal Determination (FAD) that recommends avelumab for treating adults with metastatic Merkel Cell Carcinoma (mMCC).2
FDA Grants Breakthrough Therapy Designation for Avelumab in Combination with INLYTA americanpharmaceuticalreview
December 27, 2017
Merck KGaA announced the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for avelumab in combination with INLYTA (axitinib) for treatment-naïve patients with advanced renal cell carcinoma (RCC).
EMA’s CHMP recommends Merck and Pfizer's cancer drug avelumab for approval pharmaceutical-technology
July 25, 2017
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued positive opinion recommending the approval of Merck and Pfizer's avelumab (BAVENCIO) as a monotherapy...
Merck, Pfizer’s avelumab clears first hurdle in early access scheme pharmatimes
July 25, 2017
Patients with Merkel Cell Carcinoma living in the UK are a step closer to getting early access to Merck and Pfizer’s avelumab after regulators assigned the drug Promising Innovative Medicines (PIM) status.
EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinom en-cphi.cn
July 24, 2017
Merck and Pfizer Inc. (NYSE: PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of avelumab* (BAVENCIO®)...
FDA Grants Approval for BAVENCIO (avelumab), the First Immunotherapy Approved for Metastatic Merkel en-cphi.cn
March 24, 2017
Merck and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has approved BAVENCIO(avelumab) Injection 20 mg/mL, for intravenous use, for the treatment of adults and pediatric patients 12 years and older with metastatic
Priority review for Merck, Pfizer’s avelumab in urothelial cancer pharmatimes
March 02, 2017
US regulators have agreed to undertake a priority review Merck and Pfizer's avelumab as ...
US FDA accepts priority review for EMD Serono's application for avelumab pharmaceutical-technology
March 02, 2017
The US Food and Drug Administration (FDA) has accepted priority review for EMD Serono's biologics licence application (BLA) for avelumab to treat patients with locally advanced or metastatic urothelial carcinoma (mUC).

Previous page 1 2 3 Next page